BI 1320.22DME: Safety and effect on central retinal thickness of BI 1026706 in patients with diabetic macular edema
Laufzeit: 01.01.2016 - 31.12.2018
Kurzfassung
A randomized, double-masked, placebo-controlled exploratory study to evaluate pharmacodynamics, safety and tolerability of orally administered BI 1026706 for 12 weeks in patients with mild visual impairment due to center-involved diabetic macular edema (DME)
